Ignite Creation Date:
2024-07-17 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06490744
Status:
RECRUITING
Last Update Posted:
2024-07-08
First Post:
2024-07-04
Brief Title:
Evolution of Respiratory Function in Lung Transplant Patients With Moderate to Severe Covid-19 Infection
Sponsor:
University Hospital Strasbourg France
Organization:
University Hospital Strasbourg France
Study Overview
Official Title:
Evolution of Respiratory Function in Lung Transplant Patients With Moderate to Severe SARS-Cov-2 Infection Single-center Retrospective Study
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Cov- EvoLuT
Brief Summary:
The SARS-Cov-2 infection pandemic has caused a large number of acute respiratory failures and deaths across the world Certain factors have been identified as associated with a higher risk of developing a severe form and dying Immunosuppression has been identified as a risk factor for progressing to a severe form
Lung transplant patients were particularly vulnerable during this period with a high frequency of respiratory compromise sometimes progressing towards acute respiratory distress syndrome and at a later stage towards fibrotic forms The impact of the infection on the immunological status of the patient and on the tolerance of the transplant have been little studied The various treatments implemented during the pandemic have rapidly evolved immunotherapy vaccination convalescent plasma transfusion etc which may have modulated this risk The evolution of respiratory function may be linked to the respiratory infection itself or to the severity of respiratory damage during the infection It is therefore relevant to compare patients with a moderate form of COVID-19 non-intubated patients to patients with severe forms requiring invasive ventilation in intensive care The evolution of respiratory function after infection has not yet been studied
Lung transplant patients were particularly vulnerable during this period with a high frequency of respiratory compromise sometimes progressing towards acute respiratory distress syndrome and at a later stage towards fibrotic forms The impact of the infection on the immunological status of the patient and on the tolerance of the transplant have been little studied The various treatments implemented during the pandemic have rapidly evolved immunotherapy vaccination convalescent plasma transfusion etc which may have modulated this risk The evolution of respiratory function may be linked to the respiratory infection itself or to the severity of respiratory damage during the infection It is therefore relevant to compare patients with a moderate form of COVID-19 non-intubated patients to patients with severe forms requiring invasive ventilation in intensive care The evolution of respiratory function after infection has not yet been studied
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None